Liquidia wins Federal Circuit ruling affirming invalidation of United Therapeutics' '793 patent

Liquidia Corp

Federal Circuit upheld PTAB decision finding all claims of U.S. Patent No. 10,716,793 unpatentable.
Liquidia will immediately seek to set aside the District Court injunction and pursue final FDA approval of YUTREPIA.
FDA PDUFA goal date for PH-ILD indication is January 24, 2024.
CEO Roger Jeffs stated company now has rulings that YUTREPIA does not infringe any valid claim in three initially asserted patents.
Liquidia will also seek dismissal of related claims in second Hatch-Waxman lawsuit and defend against new '327 patent allegations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.